Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin 10% - Grifols

Next Previous
Drug Profile

Immune globulin 10% - Grifols

Alternative Names: Gammaked; Gamunex; Gamunex-C; Gamunex-IGIV; IGIV; Intravenous gammaglobulin; IVIG; IVIG 10% - Kedrion; Kedrion Immunoglobulin 10%; Kedrion IVIG 10%; KIg10; TAL-05-0002

Latest Information Update: 07 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; Beth Israel Deaconess Medical Center; Grifols; Kedrion; University of Texas Southwestern Medical Center
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Polyethylene glycols; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic inflammatory demyelinating polyradiculoneuropathy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders
  • Phase III Myasthenia gravis
  • Phase II COVID 2019 infections; Diabetic neuropathies
  • Phase I/II Tachycardia
  • Discontinued Multiple sclerosis

Most Recent Events

  • 30 Dec 2024 Kedrion plans a phase III trial for Chronic inflammatory demyelinating polyradiculoneuropathy (IV) in September 2025 (NCT06752356)
  • 24 Oct 2024 Therapeutic, pharmacokinetic and adverse events data from a phase III trial in Primary Immunodeficiency presented at the (2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI-2024)
  • 04 Jan 2024 Immune globulin is still in phase III trial in Immunodeficiency disorders (In adolescents, In children) in Hungary, Slovakia, Italy (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top